CVS Health (CVS)
(Delayed Data from NYSE)
$56.94 USD
+0.47 (0.83%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $56.89 -0.05 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.94 USD
+0.47 (0.83%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $56.89 -0.05 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth F Momentum C VGM
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Time to Buy CVS Stock Before Crucial Q4 Earnings?
by Shaun Pruitt
Trading near its 52-week lows and 23% from its highs, investors will be paying close attention to CVS Health's (CVS) fourth-quarter earnings on February 8.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $86.18 in the latest trading session, marking a -1.5% move from the prior day.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health (CVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Apple, Meta Platforms, Mastercard, CVS Health and Ameriprise Financial
by Zacks Equity Research
Apple, Meta Platforms, Mastercard, CVS Health and Ameriprise Financial are included in this Analyst Blog.
Q4 Earnings Season Scorecard and Analyst Reports for Apple, Meta & Mastercard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, Inc. (META) and Mastercard Incorporated (MA).
Here's Why CVS Health (CVS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $87.78 in the latest trading session, marking a +0.14% move from the prior day.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q4.
CVS Health (CVS) to Expand Health Care Access With New Pact
by Zacks Equity Research
CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon are part of the Zacks Industry Outlook article.
Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Headwinds
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $87, moving -0.55% from the previous trading session.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Why Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Time to Buy CVS or Oak Street Health Stock on Potential Acquisition?
by Shaun Pruitt
News of CVS Health (CVS) potentially acquiring Oak Street Health (OHS) for $10 billion broke this week and highlighted what could be another lucrative acquisition in 2023.
5 Retail Stocks That Could Rally on Lower Inflation
by Shaun Pruitt
Consumer data showing signs of deflation on a month-to-month basis is promising for the broader stock market. This is especially significant for the Retail and Wholesale sector and a stronger consumer could lead to more upside in these five stocks.
The Zacks Analyst Blog Highlights JPMorgan Chase, Chevron, Salesforce, CVS Health and FedEx
by Zacks Equity Research
JPMorgan Chase, Chevron, Salesforce, CVS Health and FedEx are included in this Analyst Blog.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $89.75 in the latest trading session, marking a -0.99% move from the prior day.
Top Research Reports for JPMorgan Chase, Chevron & Salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Chevron Corporation (CVX) and Salesforce, Inc. (CRM).
Why CVS Health (CVS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
World Bank Sees Slow Growth in 2023
by Mark Vickery
The World Bank has slashed its 2023 growth projection from to +1.7% from +3% it just six short months ago.